Skip to main content
PharmaSGP Holding SE logo

PharmaSGP Holding SE — Investor Relations & Filings

Ticker · PSG ISIN · DE000A2P4LJ5 LEI · 3912005CZ12PVVCIPT91 F Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-10-28 Delisting Announcement
Country DE Germany
Listing F PSG

About PharmaSGP Holding SE

https://pharmasgp.com/english/

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive products for chronic indications, primarily utilizing natural active ingredients with a favorable side-effect profile. It holds a market-leading position in several therapeutic areas, particularly in systemic, chemical-free pain remedies with its RubaXX® (rheumatic pain) and Restaxil® (nerve pain) brand families. The portfolio also includes prominent brands such as Baldriparan® (natural sleep aid), Formigran® (migraine), Spalt® (general pain), and DESEO® and NERADIN® (sexual weakness).

Recent filings

Filing Released Lang Actions
FUTRUE increases adequate cash compensation under the squeeze-out
Delisting Announcement Classification · 1% confidence The document is a corporate announcement regarding a 'squeeze-out' process, specifically detailing an increase in the cash compensation offered to minority shareholders by the main shareholder, FUTRUE GmbH. This relates to an upcoming extraordinary general meeting. While it mentions that documents are available on the website, the core of the text is an announcement of a material change in a corporate transaction (the squeeze-out price). Given the nature of the transaction (a takeover/squeeze-out), it falls under M&A activity.
2025-10-28 English
PharmaSGP convenes extraordinary general meeting to resolve on Squeeze-out
AGM Information Classification · 1% confidence The document is a corporate news announcement regarding the convening of an extraordinary general meeting (EGM) to resolve on a squeeze-out of minority shareholders. While it mentions an upcoming meeting, it is a news release disseminated via a regulatory news service (EQS) rather than the proxy materials themselves or the final voting results. Given the nature of the announcement regarding corporate structure and shareholder rights, it falls under the category of general regulatory announcements.
2025-09-22 English
Report Publication Announcement 2025
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 2,000 characters) from PharmaSGP Holding SE regarding the upcoming publication of their half-year/Q2 financial reports. It explicitly states the date of disclosure and provides a link to where the reports will be available, rather than containing the financial reports themselves. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2025-09-19 English
PharmaSGP publishes preliminary half-year figures for 2025
Earnings Release Classification · 1% confidence The document is a corporate news release announcing preliminary, unaudited half-year financial figures for 2025. It provides key highlights such as revenue and EBITDA, but explicitly states that the full report will be published at a later date (September 25, 2025). According to the 'Menu vs Meal' rule, this is an initial announcement of results rather than the full interim report itself, making it an Earnings Release (ER). H1 2025
2025-09-11 English
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 1,315 additional shares of PharmaSGP Holding SE in delisting tender offer between the reporting date of the announcement published on August 11,
Director's Dealing Classification · 1% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR) or a person closely associated with them. It explicitly follows the standard format for 'Directors' Dealings' (insider trading disclosure), identifying the person (FUTRUE GmbH, associated with Dr. Clemens Fischer), the issuer (PharmaSGP Holding SE), the nature of the transaction (tender of shares), and the price/volume details. This aligns perfectly with the definition for 'Director's Dealing' (DIRS).
2025-08-14 English
PharmaSGP Holding SE: FUTRUE GmbH, Tender of a total of 39,678 additional shares of PharmaSGP Holding SE in the delisting tender offer between the reporting date of the announcement published on Augus
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and follows the standard regulatory format for reporting transactions by persons discharging managerial responsibilities (PDMRs) or persons closely associated with them. It details the transaction of shares by FUTRUE GmbH, which is closely associated with a member of the administrative or supervisory body (Dr. Clemens Fischer). This fits the definition of a Director's Dealing (DIRS) filing.
2025-08-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.